Next Quarterly Earnings
Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Swedish Orphan Biovitrum (Sobi) is a leading specialty pharmaceutical company that develops and markets innovative orphan drugs for rare diseases. Sobi focuses on biopharmaceuticals in hemophilia, immunology, and other therapeutic areas to sustainably improve the lives of patients.
Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Swedish Orphan Biovitrum is scheduled to report its next quarterly earnings on 10/27/2026. Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Swedish Orphan Biovitrum last reported quarterly earnings on 7/16/2026 (Q2 2026). Earnings per share (EPS) came in at 3.14 SEK.
Across its last 5 earnings reports, Swedish Orphan Biovitrum stock moved by ±2.7% on average the following day. The largest reaction was +8% on 02/05/2026; 3 of 5 reactions were positive.
Swedish Orphan Biovitrum has beaten analyst EPS estimates in 4 of its last 5 evaluated quarters (beat rate: 80%).
Use the 'Subscribe in calendar' button on this page to add all dates to Google Calendar, Apple Calendar or Outlook. Dates update automatically when they change.
Basis: price reactions to the last 5 report dates (close to close).
Basis: 5 quarters with an analyst estimate and reported EPS.
Past price reactions are not a reliable indicator of future performance.